Pazopanib is a targeted therapy medicine for certain cancers. It is marketed as Votrient and Paznib among others. The drug is indicated for the treatment of patients with advanced renal cell cancer (kidney cancer). It is also prescribed to treat metastatic soft tissue sarcoma in some patients prior to chemotherapy. It is available as tablets of strengths 200 mg and 400 mg for oral administration.

FDA Approval History:

For advanced renal...